Search

Your search keyword '"Martínez, Aurelio López"' showing total 13 results
Start Over Author "Martínez, Aurelio López"
13 results on '"Martínez, Aurelio López"'

4. Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease

Author

Lakhwani, Sunil, Mateos, María Victoria, Martínez-López, Joaquín, Paiva, Bruno, Rosinol Dachs, Laura, Martínez, Rafael, Oriol, Albert, Bargay, Joan, Gonzalez-Montes, Yolanda, Gironella, Mercedes, Encinas, Cristina, Martin, Jesus, Jarque, Isidro, Granell, Miquel, Abella, Eugenia, García Mateo, Aránzazu, Hernández-Rivas, José Ángel, Ramila, Elena, Krsnik, Isabel, Casado Montero, Luis Felipe, De Arriba, Felipe, Palomera, Luis, Sampol, Antonia, Moraleda, Jose Maria, Casanova, Maria, Delgado, Pilar, Lafuente, Ana, Amutio, Elena, Martínez, Aurelio Lopez, Altés, Albert, Ruíz, M. Ángeles, Lopez-Anglada, Lucia, Bladé Creixenti, Joan, Lahuerta, Juan-José, San-Miguel, Jesús, and Hernández, Miguel-Teodoro

Published
2022
Full Text
View/download PDF

6. Indolent Acute Myeloid Leukemia with Long Survival in Patients Treated with Best Supportive Care Only: A Pethema Registry Study

Author

Labrador, Jorge, Serrano, Josefina, Torres, Laura, Acuña-Cruz, Evelyn, Perez-Simon, Jose A., Lopez-Pavia, Maria, Rodriguez Macias, Gabriela, Botella, Carmen, Rodriguez, Carlos, Martinez Sanchez, Pilar, Amigo, Maria Luz, Cuevas, Maria Victoria, Bernal del Castillo, Teresa, Montes, María Carmen, Benavente, Celina, Rodriguez-Gutierrez, Juan Ignacio, Tormo, Mar, García-Boyero, Raimundo, Martínez, Aurelio Lopez, Lluch Garcia, Rafael, Algarra, Jesús Lorenzo, Lavilla, Esperanza, Martinez-Cuadron, David, Sanz, Miguel A., and Montesinos, Pau

Published
2022
Full Text
View/download PDF

7. Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia

Author

Megías-Vericat, Juan Eduardo, Martínez-Cuadrón, David, López, Joaquín Martínez, Bergua, Juan Miguel, Tormo, Mar, Serrano, Josefina, González, Ataulfo, de Oteyza, Jaime Pérez, Vives Polo, Susana, Vidriales, Belén, Herrera, Pilar, Vera, Juan Antonio, Martínez, Aurelio López, de la Fuente, Adolfo, Amador, Ma Lourdes, Hernández-Rivas, José-Ángel, Fernández, Ma Ángeles, Cerveró, Carlos Javier, Morillo, Daniel, Campo, Pilar Hernández, Gorrochategui, Julián, Primo, Daniel, Rojas, José Luis, Guenova, Margarita, Ballesteros, Joan, Sanz, Miguel, Montesinos, Pau, and Universitat Autònoma de Barcelona

Subjects
0301 basic medicine, Anthracycline, Daunorubicin, Pharmacology, 03 medical and health sciences, 0302 clinical medicine, Medicine, Idarubicin, Potency, ex-vivo test, Mitoxantrone, Acute myeloid leukemia, business.industry, lcsh:RC633-647.5, Myeloid leukemia, Hematology, lcsh:Diseases of the blood and blood-forming organs, Ex-vivo test, Personalized medicine, 030104 developmental biology, Infectious Diseases, 030220 oncology & carcinogenesis, Cytarabine, Original Article, business, Ex vivo, medicine.drug
Abstract

BACKGROUND: Induction schedules in acute myeloid leukemia (AML) are based on combinations of cytarabine and anthracyclines. The choice of the anthracycline employed has been widely studied in multiple clinical trials showing similar complete remission rates. MATERIALS AND METHODS: Using an ex vivo test we have analyzed if a subset of AML patients may respond differently to cytarabine combined with idarubicin, daunorubicin or mitoxantrone. Bone marrow (BM) samples of 198 AML patients were incubated for 48 hours in 96 well plates, each well containing different drugs or drug combinations at different concentrations. Ex vivo drug sensitivity analysis was made using the PharmaFlow platform maintaining the BM microenvironment. Drug response was evaluated as depletion of AML blast cells in each well after incubation. Annexin V-FITC was used to quantify the ability of the drugs to induce apoptosis, and pharmacological responses were calculated using pharmacokinetic population models. RESULTS: Similar dose-respond graphs were generated for the three anthracyclines, with a slight decrease in EC50 with idarubicin (p=1.462E-06), whereas the interpatient variability of either drug was large. To identify those cases of selective sensitivity to anthracyclines, potency was compared, in terms of area under the curve. Differences in anthracycline monotherapy potency greater than 30% from 3 pairwise comparisons were identified in 28.3% of samples. Furthermore, different sensitivity was detected in 8.2% of patients comparing combinations of cytarabine and anthracyclines. DISCUSSION: A third of the patients could benefit of the use of this test in the first line induction therapy selection, although it should be confirmed in a clinical trial specifically designed.

Published
2019

8. Outcomes after Plerixafor Plus FLAG-IDA (PLERIFLAG) Versus FLAG-IDA +/- Gentuzumab for Adult Patients with First Relapsed/Refractory AML: A Propensity Score Analysis from the Pethema Registry

Author

Bergua Burgues, Juan Miguel M., primary, Cano-Ferri, Isabel, additional, Martínez-Cuadron, David, additional, Boluda, Blanca, additional, Martínez-Sánchez, Pilar, additional, Rodríguez-Veiga, Rebeca, additional, Esteve, Jordi, additional, Vives, Susana, additional, Serrano, Josefina, additional, Vidriales, Maria-Belen, additional, Salamero, Olga, additional, Carretero, Carlos, additional, Jimenez-Ubieto, Ana, additional, Casas, Ignacio, additional, Cardesa, Rocio, additional, Diaz-Beyá, Marina, additional, Brunet, Salut, additional, Benavente, Celina, additional, Pérez-Simón, Jose Antonio, additional, Moscardo, Federico, additional, Aguiar, Eliana, additional, Perez Encinas, Manuel, additional, Martínez, Aurelio López, additional, Rguez, Carlos, additional, Cabello, A., additional, Labrador, Jorge, additional, Costilla, Lissette Del Pilar, additional, Sossa, Claudia, additional, Bernal Del Castillo, Teresa, additional, Sanz, Miguel A., additional, and Montesinos, Pau, additional

Published
2019
Full Text
View/download PDF

9. Post-Remission Treatment with Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) in Adult Patients with High-Risk (HR) Philadelphia Chromosome-Negative (Ph-neg) Acute Lymphoblastic Leukemia (ALL) According to Their Minimal Residual Disease (MRD). Final Results of the Pethema ALL-HR-11 Trial

Author

Ribera, Josep-Maria, primary, Morgades, Mireia, primary, Ciudad, Juana, primary, Montesinos, Pau, primary, Barba, Pere, primary, García-Cadenas, Irene, primary, Moreno, María José, primary, Vives, Susana, primary, Esteve, Jordi, primary, Gil, Cristina, primary, Monsalvo, Silvia, primary, Artola, María Teresa, primary, Ribera, Jordi, primary, Genescà, Eulàlia, primary, Tormo, Mar, primary, Cervera, Marta, primary, Martínez-Carballeira, Daniel, primary, Novo, Andrés, primary, González-Campos, José, primary, Soria, Beatriz, primary, Bermúdez, Arancha, primary, Martínez, Aurelio López, primary, Mercadal, Santiago, primary, Fernández-Martín, Rosa, primary, Coll, Rosa, primary, Serrano, Josefina, primary, Amigo, Maria Luz, primary, Martínez-Sánchez, Pilar, primary, Bergua, Juan-Miguel, primary, Serrano-Maestro, Alfons, primary, Giménez Conca, Alberto, primary, Barrena, Susana, primary, Granada, Isabel, primary, Feliu, Evarist, primary, and Orfao, Alberto, primary

Published
2019
Full Text
View/download PDF

10. Long-Term Efficacy and Safety (27 months) of the Biosimilar CT-P10 in Patients with Low Tumor Burden Follicular Lymphoma

Author

Kwak, Larry W, Sancho, Juan Manuel, Cho, Seok-Goo, Nakazawa, Hideyuki, Suzumiya, Junji, Tumyan, Gayane, Kim, Jin Seok, Menne, Tobias F, Mariz, Jose Mario, Ilyin, Nikolai, Jurczak, Wojciech, Martínez, Aurelio Lopez, Samoilova, Olga, Zhavrid, Edvard, Ruiz, Eduardo Yanez, Trneny, Marek, Popplewell, Leslie L., Ogura, Michinori, Kim, Won Seog, Lee, Sang Joon, Kim, Sung Hyun, Ahn, Keum Young, and Buske, Christian

Published
2020
Full Text
View/download PDF

11. Comparison of Efficacy and Safety of Biosimilar CT-P10 to Rituximab in Patients with Previously Untreated Low Tumor Burden Follicular Lymphoma (LTBFL): A Randomized Phase III Study

Author

Ogura, Michinori, Sancho, Juan Manuel, Cho, Seok-Goo, Nakazawa, Hideyuki, Suzumiya, Junji, Tumyan, Gayane, Kim, Jin Seok, Lennard, Anne, Mariz, Jose Mario, Ilyin, Nikolai, Jurczak, Wojciech, Martinez, Aurelio Lopez, Samoilova, Olga, Zhavrid, Edvard, Ruiz, Eduardo Yanez, Trneny, Marek, Popplewell, Leslie, Coiffier, Bertrand, Buske, Christian, Kim, Won Seog, Lee, SangJoon, Lee, Sungyoung, Bae, YunJu, and Kwak, Larry W

Published
2018
Full Text
View/download PDF

12. Precision Medicine Test Is Similar but Faster Than Conventional Cytogenetics Predicting Response in AML Patients and Provides Alternative Treatments

Author

Ballesteros, Joan, Martínez-Cuadron, David, Martinez Lopez, Joaquin, Bergua Burgues, Juan Miguel Miguel, Tormo, Mar, Serrano, Josefina, González, Ataulfo, Perez De Oteyza, Jaime, Vives, Susana, Vidriales, Maria-Belen, Herrera, Pilar, Vera, Juan Antonio, Martinez, Aurelio Lopez, de la Fuente, Adolfo, Barciela, Lourdes Amador, Hernandez-Rivas, Jose Angel, Fernandez Fernandez, Maria Angeles, Cervero, Carlos, Morillo, Daniel, Hernandez, Pilar, Primo, Daniel, Gorrochategui, Julian, Rojas, Jose Luis, Troconiz, Iñaki, Villoria, Jesús, Sanz, Miguel, and Montesinos, Pau

Published
2018
Full Text
View/download PDF

13. Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia.

Author

Megías-Vericat JE, Martínez-Cuadrón D, López JM, Bergua JM, Tormo M, Serrano J, González A, de Oteyza JP, Vives S, Vidriales B, Herrera P, Vera JA, Martínez AL, de la Fuente A, Amador ML, Hernández-Rivas JÁ, Fernández MÁ, Cerveró CJ, Morillo D, Campo PH, Gorrochategui J, Primo D, Rojas JL, Guenova M, Ballesteros J, Sanz M, and Montesinos P

Abstract

Background: Induction schedules in acute myeloid leukemia (AML) are based on combinations of cytarabine and anthracyclines. The choice of the anthracycline employed has been widely studied in multiple clinical trials showing similar complete remission rates., Materials and Methods: Using an ex vivo test we have analyzed if a subset of AML patients may respond differently to cytarabine combined with idarubicin, daunorubicin or mitoxantrone. Bone marrow (BM) samples of 198 AML patients were incubated for 48 hours in 96 well plates, each well containing different drugs or drug combinations at different concentrations. Ex vivo drug sensitivity analysis was made using the PharmaFlow platform maintaining the BM microenvironment. Drug response was evaluated as depletion of AML blast cells in each well after incubation. Annexin V-FITC was used to quantify the ability of the drugs to induce apoptosis, and pharmacological responses were calculated using pharmacokinetic population models., Results: Similar dose-respond graphs were generated for the three anthracyclines, with a slight decrease in EC 50 with idarubicin (p=1.462E-06), whereas the interpatient variability of either drug was large. To identify those cases of selective sensitivity to anthracyclines, potency was compared, in terms of area under the curve. Differences in anthracycline monotherapy potency greater than 30% from 3 pairwise comparisons were identified in 28.3% of samples. Furthermore, different sensitivity was detected in 8.2% of patients comparing combinations of cytarabine and anthracyclines., Discussion: A third of the patients could benefit from the use of this test in the first line induction therapy selection, although it should be confirmed in a clinical trial specifically designed., Competing Interests: Competing interests: The authors have declared that no competing interests exist.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results